These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38598270)

  • 1. Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength.
    Leanza G; Cannata F; Faraj M; Pedone C; Viola V; Tramontana F; Pellegrini N; Vadalà G; Piccoli A; Strollo R; Zalfa F; Beeve AT; Scheller EL; Tang SY; Civitelli R; Maccarrone M; Papalia R; Napoli N
    Elife; 2024 Apr; 12():. PubMed ID: 38598270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.
    Piccoli A; Cannata F; Strollo R; Pedone C; Leanza G; Russo F; Greto V; Isgrò C; Quattrocchi CC; Massaroni C; Silvestri S; Vadalà G; Bisogno T; Denaro V; Pozzilli P; Tang SY; Silva MJ; Conte C; Papalia R; Maccarrone M; Napoli N
    J Bone Miner Res; 2020 Dec; 35(12):2415-2422. PubMed ID: 32777114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone microarchitecture, biomechanical properties, and advanced glycation end-products in the proximal femur of adults with type 2 diabetes.
    Karim L; Moulton J; Van Vliet M; Velie K; Robbins A; Malekipour F; Abdeen A; Ayres D; Bouxsein ML
    Bone; 2018 Sep; 114():32-39. PubMed ID: 29857063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of advanced glycation end products in fracture risk assessment in postmenopausal type 2 diabetic patients.
    Gao L; Liu C; Hu P; Wang N; Bao X; Wang B; Wang K; Li Y; Xue P
    Front Endocrinol (Lausanne); 2022; 13():1013397. PubMed ID: 36578954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Mechanical, Material, and Compositional Determinants of Human Trabecular Bone Quality in Type 2 Diabetes.
    Sihota P; Yadav RN; Dhaliwal R; Bose JC; Dhiman V; Neradi D; Karn S; Sharma S; Aggarwal S; Goni VG; Mehandia V; Vashishth D; Bhadada SK; Kumar N
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2271-e2289. PubMed ID: 33475711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.
    Heilmeier U; Carpenter DR; Patsch JM; Harnish R; Joseph GB; Burghardt AJ; Baum T; Schwartz AV; Lang TF; Link TM
    Osteoporos Int; 2015 Apr; 26(4):1283-93. PubMed ID: 25582311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SiJunZi decoction ameliorates bone quality and redox homeostasis and regulates advanced glycation end products/receptor for advanced glycation end products and WNT/β-catenin signaling pathways in diabetic mice.
    Dai X; Liu Y; Liu T; Zhang Y; Wang S; Xu T; Yin J; Shi H; Ye Z; Zhu R; Gao J; Dong G; Zhao D; Gao S; Wang X; Prentki M; Brὂmme D; Wang L; Zhang D
    J Ethnopharmacol; 2024 Jan; 319(Pt 2):117167. PubMed ID: 37716489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation.
    Li Y; Wang L; Zhang M; Huang K; Yao Z; Rao P; Cai X; Xiao J
    Cell Prolif; 2020 Jun; 53(6):e12834. PubMed ID: 32468637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and rescue of skeletal fragility in a high-fat diet mouse model of type 2 diabetes: An in vivo and in vitro approach.
    LLabre JE; Sroga GE; Tice MJL; Vashishth D
    Bone; 2022 Mar; 156():116302. PubMed ID: 34952229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway.
    Zhang M; Li Y; Rao P; Huang K; Luo D; Cai X; Xiao J
    Cell Prolif; 2018 Oct; 51(5):e12471. PubMed ID: 30014569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.
    Karim L; Bouxsein ML
    Bone; 2016 Jan; 82():21-7. PubMed ID: 26211993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of bone fragility by pulsed electromagnetic fields in type 2 diabetic KK-Ay mice involving Wnt/β-catenin signaling.
    Shao X; Yang Y; Tan Z; Ding Y; Luo E; Jing D; Cai J
    Am J Physiol Endocrinol Metab; 2021 May; 320(5):E951-E966. PubMed ID: 33719588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
    J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.
    Furst JR; Bandeira LC; Fan WW; Agarwal S; Nishiyama KK; McMahon DJ; Dworakowski E; Jiang H; Silverberg SJ; Rubin MR
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2502-10. PubMed ID: 27115060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating serum microRNAs including senescent miR-31-5p are associated with incident fragility fractures in older postmenopausal women with type 2 diabetes mellitus.
    Heilmeier U; Hackl M; Schroeder F; Torabi S; Kapoor P; Vierlinger K; Eiriksdottir G; Gudmundsson EF; Harris TB; Gudnason V; Link TM; Grillari J; Schwartz AV
    Bone; 2022 May; 158():116308. PubMed ID: 35066213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes.
    Eckhardt BA; Rowsey JL; Thicke BS; Fraser DG; O'Grady KL; Bondar OP; Hines JM; Singh RJ; Thoreson AR; Rakshit K; Lagnado AB; Passos JF; Vella A; Matveyenko AV; Khosla S; Monroe DG; Farr JN
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32267250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal alterations in bone morphometry, mechanical integrity and composition in Type-2 diabetes in a Zucker diabetic fatty (ZDF) rat.
    Monahan GE; Schiavi-Tritz J; Britton M; Vaughan TJ
    Bone; 2023 May; 170():116672. PubMed ID: 36646266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HFD-Fed/Low-Dose STZ-Treated Female Sprague-Dawley Rat Model to Investigate Diabetic Bone Fragility at Different Organization Levels.
    Sihota P; Yadav RN; Poleboina S; Mehandia V; Bhadada SK; Tikoo K; Kumar N
    JBMR Plus; 2020 Oct; 4(10):e10379. PubMed ID: 33103024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.